Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs H 1PV (Primary) ; H 1PV (Primary) ; H 1PV (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oryx GmbH & Co
- 12 Jun 2015 Results will be presented at the 9th International Conference on Oncolytic Virus Therapeutics and at the BIO International Convention, according to an Oryx GmbH & Co media release.
- 27 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2015 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.